High Tide (HITI) Q3 2026 Earnings Call Transcript

High Tide reported record fiscal Q3 revenue of CAD 198.8 million, up 33% year over year, while adjusted EBITDA rose 52% to CAD 16.2 million and operating income increased 133% to CAD 8.7 million. Free cash flow reached CAD 7.0 million and cash increased CAD 10.6 million to CAD 47.1 million, supporting Canadian store expansion and rapidly scaling German medical-cannabis distributor Remexian. Remexian revenue grew 21% sequentially to CAD 38.2 million and distribution volume rose 35% to 10.2 tonnes, though Canadian same-store sales remained flat amid inflation-driven smaller baskets and intensifying competition.

Analysis

HITI’s investable inflection is not the reported earnings beat but the potential transition from a low-quality Canadian retail multiple to a two-engine cash-flow compounder. Incremental German distribution volume should carry materially higher contribution profit if procurement advantages persist, while Canadian fixed-cost absorption can protect consolidated EBITDA even in a flat same-store-sales environment. The key valuation question is whether reported free cash flow remains positive after receivables growth and new-store capex; operating cash flow before working capital is encouraging but is not a substitute for cash conversion.

Competitive pressure in Canada is likely to accelerate weaker independents’ exits rather than impair the scaled chains equally. HITI’s membership base lowers customer-acquisition expense and supports repeat traffic, but copycat discounting could keep basket values and gross margins capped for the next 1-3 quarters. That makes sector peers with less scale, weaker loyalty programs, or higher leverage more exposed to store-level deleveraging; CURA’s potential consolidation of Aurora would also reduce one independent Canadian supply competitor, potentially improving HITI’s supplier optionality rather than creating a direct retail threat.

Germany is the principal 6-18 month upside catalyst, but management’s margin outlook requires verification: import-quota disruptions can shift revenue, inventory and receivables across quarters, while sub-9% factoring embeds a financing cost that becomes more consequential as the segment scales. Consensus may be underestimating the value of an asset-light distributor able to source from multiple producers, but may also be over-annualizing a quarter aided by unusually strong volume growth and non-cash accounting gains. Falsify the thesis if German segment gross margin falls below the low-20s, receivables/factoring expand faster than sales for two quarters, Canadian traffic turns negative, or free cash flow is consumed by working capital and openings.

Key Decisions for Investors

• Initiate a small long HITI only after verifying reported German market-share data and receivables aging in the next filing; target a 6-12 month rerating on sustained positive free cash flow and mid/high-20s German gross margin. Size as a liquidity-constrained small-cap position; exit on two consecutive quarters of negative free cash flow excluding discretionary expansion capex.
• Use a HITI long / CURA short relative-value basket over 3-6 months if Canadian pricing competition intensifies: HITI’s loyalty-led traffic retention and asset-light European sourcing should be relatively more defensive, while CURA carries greater integration and capital-allocation risk. Do not initiate if CURA/Aurora transaction terms imply unusually accretive international supply synergies or if HITI’s Canadian same-store sales turn materially negative.
• Set an event alert for German import-quota approvals and BfArM market-share releases. A short-lived quota-driven volume interruption without margin or customer loss would be a better HITI entry point than chasing post-earnings momentum; a prolonged disruption beyond roughly 6-8 weeks would invalidate the near-term volume thesis.
• Avoid extrapolating the accounting net-income figure into valuation. Underwrite HITI on adjusted EBITDA, interest/factoring costs, working-capital intensity and per-share free cash flow; monitor debt utilization and share count before adding exposure.